Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
8 evidence topics · 7 sources
Treatment goal: continuous complete control and normal quality of life
“The goal of treatment is to treat the disease until it is gone, as efficiently and as safely as possible, aiming at a continuous complete control (consistently UAS = 0/UCT = 16) and a normalization of quality of life” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall aim of the management in urticaria is to achieve complete control of symptoms and maintain effective and safe treatment until the disease is gone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The UCT cutoff value for well-controlled disease is 12 out of 16 possible points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer statement of complete response as the treatment goal
Complete control and complete response rates in practice, CURE registry
“We report real-world data from the global Chronic Urticaria Registry (CURE)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response after treatment escalation, CURE registry
“This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complete response was defined as UCT = 16 with a ≥ 3-point increase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH1-AH), 6.0% (licensed-dose sgH1-AH to up-dosed sgH1-AH), and 28.4% (any dose sgH1-AH to omalizumab) achieved complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uncontrolled disease at Month 24 in antihistamine-refractory CSU, AWARE study sponsored by the manufacturer of omalizumab
“AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world omalizumab complete response rate, meta-analysis supported by Novartis
“In this meta-analysis of 67 published reports on real-world effectiveness, omalizumab therapy was associated with an average 25.6-point improvement in weekly Urticaria Activity Score (vs a 14.9 to 22.1 point improvement reported in clinical trials), a 4.7 point improvement in Urticaria Activity Score, a complete response rate of 72.2%, a partial response rate of 17.8%, and an average adverse event rate of 4.0% (vs 2.9%-8.0% reported in clinical trials).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was supported by Novartis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Barzolvolimab phase 3: complete response (UAS7=0) at Week 12
| Arm, Week 12 | EMBARQ-CSU1 | EMBARQ-CSU2 |
|---|---|---|
| Placebo | “9.3%” | “12.6%” |
| 150 mg Q4W | “42.4% (p<.00001)” | “45.7% (p<.00001)” |
| 300 mg Q8W | “42.1% (p<.00001)” | “44.0% (p<.00001)” |